Kidney disease targeted by Noxxon's mirror-image oligonucleotides
This article was originally published in Scrip
Noxxon Pharma has started its first clinical study with its "Spiegelmer" compounds. These are mirror-image oligonucleotides (L-aptamers) which are not metabolised and do not interact with normal nucleic acids, but do bind to pharmacologically active target molecules.
You may also be interested in...
Verona Pharma’s candidate COPD therapy ensifentrine has a first-in-class dual mechanism of action and is to be explored as an add-on to LAMA and LABA therapy in two Phase III clinical studies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Bavencio’s Survival Benefit Confirmed In Front-Line Maintenance Therapy For Advanced Urothelial Cancer
Further details of Merck KGaA/Pfizer-funded JAVELIN Bladder 100 study presented at this year’s ASCO confirm avelumab’s survival benefit when used as front-line maintenance therapy in patients with advanced urothelial cancer that has not progressed following initial chemotherapy.